Single Peptides · Exact presentation
IGF-1 LR3 · 1 mg Vial
IGF-1 LR3 · 1 mg Vial is an exact single peptide or compound entry. This strength is kept separate because concentration and calculations depend on vial amount.
Educational research information for this exact variation. It is not medical advice, a prescription, or proof of regulatory approval.
Separate commercial record
Availability in the Dominican Republic
This educational entry is separate from the live catalog. Check the exact commercial record for current availability, price, and lot documentation. View exact commercial record.
Dosing & Reconstitution Guide
For a 1 mg presentation, the reference concentration of 0.333 mg/mL mathematically corresponds to 3.003 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 0.333 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.0033 mg at this concentration.
Standard / Gradual Approach (3 mL = ~0.333 mg/mL)
The source chart summarizes “20 mcg–50 mcg” at “Daily” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.
Standard / Gradual Approach (3 mL = ~0.333 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 20 mcg (0.02 mg) | 6 units (0.06 mL) |
| Weeks 3–4 | 40 mcg (0.04 mg) | 12 units (0.12 mL) |
| Weeks 5–8 | 50 mcg (0.05 mg) | 15 units (0.15 mL) |
Reconstitution Steps
For a 1 mg presentation, the reference concentration of 0.333 mg/mL mathematically corresponds to 3.003 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 0.333 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.0033 mg at this concentration.
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable for 1+ year.[5]
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks and avoid freeze–thaw.[6]
Allow vials to reach room temperature before opening to reduce condensation uptake.
How This Works
It relates to the growth-hormone-releasing hormone, secretagogue receptor, and GH/IGF-1 axis. Each molecule acts at a different point and should not be treated as interchangeable.
Potential Benefits & Side Effects
GH/IGF-1 signaling is systemic and may carry metabolic, endocrine, and proliferative risks. No clinical regimen is provided here.
Potential Research Observations:
Evidence ranges from medicines authorized for limited indications to experimental secretagogues with sparse human data. Evidence for the ingredient, formulation, and use must be separated.
Important Safety Considerations:
GH/IGF-1 signaling is systemic and may carry metabolic, endocrine, and proliferative risks. No clinical regimen is provided here.
Preparation:
For a 1 mg presentation, the reference concentration of 0.333 mg/mL mathematically corresponds to 3.003 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 0.333 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.0033 mg at this concentration.
Source trail
Scientific references and source discovery
- PeptideDosages — exact IGF-1 LR3 · 1 mg Vial entrysecondary-structure
- PubMed — literature search for IGF-1 LR3primary-discovery
- ClinicalTrials.gov — study search for IGF-1 LR3trial-registry
- View Sourcesource-reference
- View Sourcesource-reference